The Senate Health, Education, Labor and Pensions (HELP) Committee will vote on President Trump’s nominee for commissioner of the U.S. Food and Drug Administration (FDA), Scott Gottlieb, MD, next Wednesday, April 26.
As we have reported, Dr. Gottlieb answered questions about the opioid epidemic, drug pricing, potential conflicts of interest, and more during his nomination hearing three weeks ago. A focal point during the hearing was the nation’s opioid crisis, which Dr. Gottlieb said would require “dramatic action” on the part of the agency and, if confirmed, he would make his first priority.
Gottlieb is a clinical assistant professor at New York University School of Medicine, a resident fellow at the conservative American Enterprise Institute, and an internist at New York’s Tisch Hospital. In addition, he is a venture partner at New Enterprise Associates, a large venture capital firm that is heavily invested in medical technology and healthcare companies; an independent director at Tolero Pharmaceuticals; and a member of GlaxoSmithKline's product investment board, among other current roles. His past government roles have included serving as deputy commissioner for medical and scientific affairs at the FDA, as well as senior policy advisor to the administrator at CMS, where he worked on implementation of the Medicare Prescription Drug, Improvement, and Modernization Act and the Medicare Part D drug benefit.
If Dr. Gottlieb clears the HELP Committee, the next step would be a floor vote in the Senate. We will keep you updated.